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Mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) is an important source of 
HIV-1 infection in infants, and can occur at any point, including in utero, at the time of delivery, and via 
breastfeeding. In the absence of intervention, such as the use of antiretroviral therapy (ART), MTCT of HIV-1 during 
pregnancy or delivery can affect approximately 15–25% of infants, with a further 5–20% of infants becoming 
infected postnatally during breastfeeding. The use of maternal ART while breastfeeding reduces the MTCT risk 
from 35% without any intervention to less than 5%. Although a significant improvement, 5% of infants continue to 
be infected.i Maternal factors that contribute to this continued risk of transmission despite taking ART include the 
method of feeding, breast health, RNA and DNA viral load in breast milk and plasma, and maternal nutrition. Infant 
factors such as the disruption in the integrity of the gastrointestinal mucosal surfaces also contribute to an increased 
rate of MTCT.  
 
Aims: This literature review aimed to investigate why breastfeeding is still a risk factor despite HIV-1-infected 
mothers being on effective combination ART (cART)? This review will explore the associated factors that contribute 
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Introduction 
Breastfeeding is recognized for its effective role in 
significantly decreasing the risk of childhood 
morbidity, which includes gastrointestinal and 
respiratory infections. 2  The World Health 
Organization (WHO) recommends that, on a 
population basis, infants should be breastfed 
exclusively for the first 6 months of life for optimal 
health benefits.3 However, despite these significant 
benefits, breastfeeding serves as a possible route for 
HIV-infected mothers to transmit HIV to their infants. 
4  Without intervention, HIV-infected mothers will 
transmit their infection to their infants during 
pregnancy or delivery in approximately 15–25% of 
cases, with a further 5–20% of infants becoming 
infected postnatally during breastfeeding, resulting 
in an overall risk of 30–45%. At the end of 2011, 
approximately 3.4 million children were infected 
with HIV, with 91% living in sub-Saharan Africa.4 
Therefore, reducing MTCT while maximizing the 
benefits of breastfeeding is evidently a public health 
dilemma, and addressing this has the potential to 
save many lives.  
 
The main risk factors for postnatal transmission 
through breastfeeding relate to the control of HIV 
virus replication in maternal blood or breast milk. 
Maternal CD4 cell count, different HIV strains, RNA 
viral load in maternal plasma and breast milk, and 
breast pathologies such as mastitis are all strongly 
associated with an increased risk of transmission.5 
Furthermore, the type of feeding provided to the 
infant can have an impact on the transmission. The 
2013 WHO principles and recommendations and 
the Center for Disease Control and Prevention 
(CDC) have published recommendations on HIV and 
infant feeding stratified according to income. For 
mothers in low- and middle-income countries, the 
WHO recommended that, in the absence of 
antiretroviral therapy (ART), breastfeeding should be 
implemented for the “first 6 months of life unless 
replacement feeding is acceptable, feasible, 
affordable, sustainable and safe for them and their 
infants”.3 Additionally, breastfeeding should be 
continued when ART treatment has commenced. In 
contrast, the CDC recommended that HIV-1-
infected women in high-income countries should 
refrain from breastfeeding and provide safe 
replacement feeding, even when taking ART.6 
Exclusive breastfeeding for 6 months has been 
associated with a threefold decreased risk of MTCT 
of HIV-1 when compared with non-exclusive (mixed 
feeding or non-exclusive breastfeeding).5 Therefore, 
promoting and encouraging the most appropriate 
feeding will help control and minimize this important 
risk factor.  
 
WHO policy calls for universal access to ART in 
pregnant and breastfeeding mothers, but in fact, 
WHO reports suggest that in the African region, only 
63% of individuals eligible for treatment were 
actually able to access it in 2012.7 In low-resource 
settings, women should be encouraged to 
breastfeed unless their individual circumstances 
enable a regular and sufficient supply of formula milk 
for exclusive use and facilities for sterile preparation; 
this tends to be an exception. While the most 
successful strategy to eliminate postnatal HIV 
transmission would be the complete avoidance of 
exposure to breast milk, increased infant morbidity 
and mortality has been associated with the use of 
infant formula where there is a lack of clean water 
and proper hygiene in formula preparation. 
 
The prevention of mother-to-child transmission of 
HIV (PMTCT) is one of the most pressing public 
health concerns and, despite the use of 
interventions including ART, there is still a risk that 
the infection will successfully pass onto the infant. It 
is thought that the MTCT rate for women taking 
combined ART (cART) while breastfeeding reduces 
from 35% in the untreated population to less than 
5%.1,8 Given that an estimated 1.5 million HIV-
positive women become pregnant annually, this 
figure is appreciable. This review seeks to describe 
reasons for continued infection risk to the breastfed 
infant despite effective cART and the arising clinical 
and research implications.  
 
Methodology  
An initial discussion and literature review focused 
the physiology of HIV-1 replication in maternal 
blood or breast milk. Noting the limited number of 
papers on HIV-1 replication and the effect on MTCT, 
a question was formed to explore the reasons for 
MTCT of HIV-1 focusing on HIV-1 replication in 
breast milk and plasma. The following databases 
were used to identify appropriate studies: 
MEDLINE, Google Scholar, and Scopus. Electronic 
journals, such as the British Medical Journal (BMJ), 
the Lancet, and Journal of the American Medical 
Association were also used.  The search terms used 




Table 1: Search terms (used in 
combination with each other) 
•! HIV-1 transmission rate 
•! Breastfeeding 
•! HAART* 
•! Formula feeding 
•! HIV viral load 
•! RNA and DNA  
•! Cell associated 
•! Cell free 
•! Antiretroviral therapy 
*HAART = highly active antiretroviral therapy 
 
After having searched the specific terms on the 
various databases, few relevant studies were found; 
most focused on MTCT rates among breastfeeding 
HIV-1-infected mothers. A limitation was that the 
outcome measure, i.e. cumulative transmission rate, 
was not present in all studies, which made 
comparison between studies difficult. Four eligible 
studies, with a focus on the effect of breastfeeding 
on HIV transmission rate, were evaluated and 
reviewed. The studies also explored the cumulative 
MTCT of HIV-1 in breastfeeding and formula-
feeding infants, and a further eight compared 
different ART regiments in preventing HIV 
transmission during breastfeeding. The data from 
these eight studies was summarized by one review 
paper, which compared the cumulative transmission 
rates between different regimens of ART used. The 
data was then evaluated in this review and the 
reasons for the presence of transmission rates in 
spite of ART were explored. 
 
HIV transmission through breastfeeding 
Several observational studies and randomized 
controlled trials (RCTs) have investigated the 
effectiveness of maternal ART in the reduction of 
MTCT rates of HIV-1 in infants who were breastfed. 
Results from Table 1 show that maternal triple ART 
prophylaxis does effectively reduce MTCT in 
comparison with no ART (as seen in Table 2); 
however, MTCT rates still exist and continue to 
increase from 4 weeks to 24 months. Findings from 
these studies also indicate the effectiveness of infant 
ART prophylaxis in reducing postnatal HIV 
transmission during breastfeeding. Studies that give 
a combination of infant short-dose nevirapine plus 
zidovudine (sdNVP+ZDV) for 7 days, have a higher 
reduction in the MTCT rate than those who give only 
infant sdNVP or ZDV with 3TC. 
 
 
Ndauti et al. 2000 
A RCT conducted in Kenya (Ndauti et al. 2000), 
consisted of 425 antiretroviral-naïve women, of 
whom 212 were randomly assigned to breastfeed 
their infants and 213 to use formula feeding.16 The 
results showed that the cumulative HIV-1 infection 
rate at 24 months was 36.7% in the breastfeeding 
group and 20.5% in the formula-feeding group.16 
Moreover, the breastfeeding group was associated 
with a significantly lower HIV-1-free survival rate as, 
at 2 years, the rate of HIV-1-free survival was 58.0% 
in the breastfeeding group versus 70.0% in the 
formula group (p = 0.02). An important aspect to 
consider in this and all other trials that investigate 
the risk of HIV-1 transmission with breastfeeding is 
compliance with the feeding modalities that were 
assigned to the mothers. Reported compliance was 
96.0% in the breastfeeding group and 70% in the 
formula-feeding group (defined as “complete 
avoidance of breast milk”). This may limit 
interpretation of results, since compliance is usually 
self-reported and is a difficult factor to control.16 
 
Thior et al. 2006 
In contrast, Thior et al. 200617 undertook a RCT 
among 1200 women to investigate the difference in 
efficacy in reducing postnatal MTCT of HIV between 
breastfeeding and infant ZDV prophylaxis for 6 
months and formula-feeding with 1-month-old infant 
ZDV prophylaxis. The results of this trial showed that 
the cumulative HIV-1 infection rate at 18 months was 
higher in breastfed children than in the formula-fed 
children despite the addition of 6 months of ZDV 
prophylaxis; cumulative HIV-1 infection rate 9.5% 
and 6.0%, respectively yielding p = 0.02. However, 
compliance was an issue as full adherence to formula 
feeding and exclusive breastfeeding was reported at 
93.0% and 57.1% at month 18 and 6, respectively. 
Similarly to Ndauti et al. 2000, there were 
significantly higher mortality rates in the formula-
feeding group than the breast fed group, especially 
in the first 7 months, mainly due to diarrhoeal 
disease. The cumulative death rate in the formula-
fed group was 9.3% compared with 4.9% in the 
breastfed group, with a 4.4% mortality rate 
difference, which halved by 18 months.17 
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Results of studies 
 
Table 1. Comparison of the effect of maternal ART prophylaxis (postpartum) on MTCT rates of HIV-1 on breastfed infants 
Mother-to-child cumulative transmission rates of HIV-1 for infants in the breastfeeding arm with mothers on ART prophylaxis 




Cumulative HIV-1 infection rate (%) 
At birth 4 weeks 6 weeks Months 
6 9 12 24 
DREAM (Palombi et al. 
2007)Error! Bookmark not defined. 
Mozam-
bique 
Observational Triple ART sdNVP+ZDV  for 
7 days 
--- 1.2  2.2 --- --- --- 
KiBS (Thomas et al. 2011) Kenya Observational Triple ART sdNVP 2.5 --- 4.2 5 --- 5.7 7 
MITRA PLUS (Kilewo et al. 
2009)11 
Tanzania Observational Triple ART ZDV+3TC for 7 
days 
--- --- 4.1 5 --- --- --- 
Amata (Peltier et al. 
2009)12 
Rwanda Observational Triple ART sdNVP+ZDV  for 
7 days 
1.3 --- 1.3 --- 1.8 --- --- 
Kesho Boro (Kesho Boro 
et al. 2011)13 
Kenya RCT Triple ART sdNVP+ZDV  for 
7 days 
1.8 --- 3.3 4.9 --- 5.4 --- 
Mma Bana (Shapiro et al. 
2010)14 
Botswana RCT ZDV/3TC/ 
LPV/r 
sdNVP+ZDV  for 
4 weeks 
--- --- 1.1 --- --- --- --- 
Bana (Shapiro et al. 
2010)14 
Botswana RCT ZDV/3TC/ 
ABC 
sdNVP+ZDV  for 
4 weeks 
--- --- 1.1 --- --- --- --- 
BAN (Jamieson et al.  
2012)15 
Malawi RCT Triple ART sdNVP+ZDV  for 
7 days 
--- --- 2.9 --- 4 --- --- 
 
KEY: 
ART = antiretroviral therapy, HIV-1 = human immunodeficiency virus type 1, RCT = randomized control trial, sdNVP = short-dose nevirapine, ZDV = zidovudine, 3TC = lamivudine,  






ART = antiretroviral therapy, HIV-1 = human immunodeficiency virus type 1, sdNVP= short-dose nevirapine, ZDV = zidovudine, 3TC 
= lamivudine. 
 
Kilewo et al. 2009 and Dabis et al. 2005 
Two other trials, Kilewo et al. 200911 and Dabis et al. 
2005,18 demonstrated the efficacy of cART, which 
involves three antiretrovirals: ZDV, lamivudine (3TC), 
and nevirapine (NVP). Kilewo et al. 2009 carried out 
a non-randomized prospective cohort study where 
441 HIV-1 infected pregnant women were given 
ZDV, 3TC, and NVP. cART started at 34 weeks’ 
gestation and mothers were advised to exclusively 
breastfeed until 5–6 months, whereby weaning 
should be commenced. The results concluded that 
cART, which is a combination of at least three ART 
drugs, initiated at 34 weeks’ gestation and during 
breastfeeding, resulted in a low HIV transmission 
rate.19 Even though in the breastfeeding group of 
Thior et al. 2006 the infants were given 6 months of 
ZDV, the cumulative infection rate at 18 months is 
lower in Kiwelo et al. 2009 suggesting that HAART 
given to women is more beneficial than infant 
prophylaxis.11 The Dabis et al. 2005 cohort study 
included 1144 HIV-1-infected pregnant women and 
first evaluated the effectiveness of maternal 
peripartum ZDV regimen followed by a single dose 
of sdNVP during labour and infant prophylaxis with 
ZDV and sdNVP in 2001–2002. The trial then 
evaluated the effectiveness of the same regimen 
with the addition of maternal 3TC in 2002–2003. 
Women were advised to either exclusively 
breastfeed or use breast milk substitutes (formula 
feeding). The cumulative infection transmission rate 
at 6 weeks for the group of women receiving 
ZDV+sdNVP was 6.5% and 4.7% for the group 
receiving ZDV+3TC+sdNVP. Moreover, this trial had 
also evaluated the effectiveness of using maternal 
ZDV alone between 1995–2001, concluding a 
cumulative infection transmission rate of 12.5%. 
Even though the infection transmission rate was 
lower in the ZDV+3TC+sdNVP compared with 
ZDV+sdNVP, there was a 72% reduction in the 
infection transmission rate in the group of women 
receiving ZDV+sdNVP, as compared with the group 
receiving ZVD alone.18 
 
Discussion 
While several studies of maternal or infant ART 
prophylaxis during breastfeeding have shown 
Table 2. Comparison of MTCT rates of HIV-1 for infants between the breastfeeding arms and the formula-feeding arms 
Mother-to-child cumulative transmission rates of HIV-1 for infants in the breastfeeding and formula-feeding arms 
Study Group Cumulative HIV-1 infection rate (%) 
At 
birth 
4 weeks 6 weeks 14 
weeks 
  Months 
3 6 7 12 18 24 
Kenya 
(Ndauti et al. 
2000)16 
Breastfed (No ART) 7.0 --- 19.9 24.5 --
- 
28.0 --- 32.3 --- 36.7 
Formula-fed (No ART) 3.1 --- 9.7 13.2 --
- 
15.9 --- 18.2 --- 20.5 
Botswana 
(Thior et al. 
2006)17 
Breastfed + 6 months 
Infant ZDV 
3.3 4.6 --- --- --
- 
--- 9.0 --- 9.5 --- 
Formula -fed + 1 
month Infant ZDV 
3.8 5.0 --- --- --
- 
--- 5.6 --- 6.0 --- 
Tanzania 






--- --- 4.1 --- --
- 
5.0 --- 5.8 6.0 --- 
Abidijan 




--- --- 6.5 --- --
- 
--- --- --- --- --- 
Formula-fed  
ZDV+sdNVP 
--- --- --- --
- 
--- --- --- --- --- 
 Breastfed  
ZDV+3TC+sdNVP 
--- --- 4.7 --- --
- 
--- --- --- --- --- 
 Formula-fed 
ZDV+3TC+sdNVP 
--- --- --- --
- 
--- --- --- --- --- 
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significant reductions in the cumulative HIV-1 
infection transmission rate, postnatal transmission 
continues to occur, regardless of optimal treatment. 
Therefore, the development of strategies and the 
understanding of the mechanism of transmission of 
the virus will help to prevent HIV transmission via 
breastfeeding. For preventative strategies to be 
implemented, however, it is important to 
understand the reasons for continued postnatal 
infection, therefore this paper will aim to discuss the 
mechanisms and risk factors of breast milk 
transmission (summarized in table 3). 
 
Table 3: Maternal factors associated with the 
transmission of HIV-1 through breastfeeding.20,21 
- Feeding method 
- Breast health – subclinical or clinical mastitis, 
abscess, cracked nipples  
- RNA viral load in plasma 
- RNA viral load in breast milk 
- CD4+ cell count  
- Maternal nutritional status 




The type of infant feeding influences MTCT rates 
significantly, regardless of ART mothers may be 
receiving. Exclusive breastfeeding for up to 6 
months is associated with approximately a three- to 
four-fold decreased risk of postnatal transmission of 
HIV compared with mixed feeding or early 
weaning.3 
 
If the conditions for exclusive replacement feeding 
are present, then breastfeeding should be avoided. 
In the ZVITAMBO study in Zimbabwe, the reported 
rates of postnatal HIV transmission at 6 weeks were 
5.1, 6.7, and 10.5 infections per 100 child-years of 
breastfeeding for infants who were exclusively 
breastfed, predominantly breastfed, and mixed 
breast fed respectively.22 Reasons for the increased 
protection provided by exclusive breastfeeding are 
incompletely understood. Even though HIV 
transmission occurs with breastfeeding, not 
breastfeeding also carries other significant health 
risks: formula feeding and mixed feeding can 
increase the risk of infant morbidities such as 
diarrhoea and respiratory infections.5  
 
Breast health 
Furthermore, mixed breastfeeding is a significant 
risk factor for HIV transmission as the temporary 
gaps in breastfeeding cause milk stasis in the breast 
and, as a consequence of this, breast engorgement 
and risk of mastitis follow.22 Mastitis, classified as 
clinical or subclinical, is an inflammatory process 
occurring in the breast, whereby paracellular 
pathways between the mammary alveolar cells 
dilate, which results in an infiltration of inflammatory 
cells and extracellular fluid into the milk. 
Consequently, the presence of the plasma 
components and inflammatory cells, such as HIV-1 
infected lymphocytes, in breast milk can cause the 
transmission risk to increase.23,24 It is thought that, 
due to = immune activation in the breast, activated 
cells induce viral replication in breast epithelium and 
subsequently activate infant enterocytes.25 Although 
clinical mastitis is rare, subclinical mastitis accounts 
for approximately 50% of all HIV transmission 
associated with breastfeeding; it has no clinical 
symptoms, but it is associated with an increase in 
milk sodium or potassium and inflammatory 
cytokines. This abnormal increase in sodium and 
potassium results from disrupted cell membranes, 
which also contribute to greater leakage of HIV from 
plasma to breast milk.22,25 A study in Malawi 
investigating the risk factors for vertical transmission 
of HIV-1 via breastfeeding found elevated sodium 
levels consistent with mastitis was present in 16.4% 
of HIV-1-infected women. Moreover, elevated 
breast milk sodium concentration was associated 
with significantly fewer CD4+ lymphocytes and 
significantly higher plasma and breast milk HIV-1 
load (median HIV-1 load 920 copies/mL versus 
undetectable [<200 copies/mL]), which in turn was 
associated with an increased vertical transmission 
rate of HIV-1 at 6 weeks and 12 months compared 
with those women with a normal sodium range.23 
 
RNA and DNA viral load in plasma and breast milk 
Furthermore, the roles of cell-free (RNA) and cell-
associated (DNA) HIV-1 in breast milk transmission 
remains poorly understood. In an HIV-infected 
mother, both cell-free and cell-associated HIV-1 are 
found in beast milk; the virus could either be 
produced in the systemic compartment before 
entering the breast compartment or locally in 
infected lymphocytes.26 It has been suggested that 
increased levels of both cell-free virus and cell-
associated virus in maternal plasma and breast milk 
are linked to an increased risk of transmission.27 A 
case-control study in South Africa investigated the 
relationship between cell-free and cell-associated 
HIV-1 in breast milk and the potential risk of 
postnatal transmission at 6 weeks and 6 months. The 
study included 36 mothers as cases who had 
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transmitted HIV-1 to their infant through 
breastfeeding, and 36 mothers as controls who were 
non-transmitting HIV-1 infected. The study 
concluded that postnatal HIV-1 transmission was 
positively correlated with both cell-free and cell-
associated virus levels in breast milk; transmission 
was most likely with cell-associated virus levels per 
mL than cell-free virus at 6 weeks. In addition, 
transmitting mothers were more likely to have a 
higher plasma viral load (p < 0.001) and a lower 
antenatal CD4 cell count (p < 0.001). In comparison 
to mothers with an antenatal CD4 count of minimum 
500 cells/mm3, mothers with a CD4 count below 500 
cells/mm3 had a significantly higher log10 cell-free 
and cell-associated virus levels in breast milk. 
 
There are suggestions that antiretroviral treatment 
has different effects on cell-free and cell-associated 
virus in breast milk. Results from two independent 
RCTs suggested that ART (either short-course ZDV, 
sdNVP, combined ZDV/sdNVP, or short-course 
HAART) given prior to or post-delivery significantly 
suppressed cell-free HIV-1 but not cell-associated 
HIV-1 loads in breast milk.8,28 Therefore, since cell-
associated HIV-1 virus in breast milk is not affected 
by maternal ART, this might account for the 
remaining HIV-1 transmission during breastfeeding. 
 
Maternal nutritional status 
Maternal nutritional status can also influence the risk 
of HIV transmission via breastfeeding. Vitamin A 
deficiency is a highly prevalent nutritional deficiency 
that affects approximately 19 million pregnant 
women.29 Vitamin A is essential for the mother and 
the development of the fetus. Its main role is in 
strengthening the immune system’s defence against 
infection via the differentiation of immune cells such 
as lymphocytes.29 Early observational trials had 
suggested an association between low serum 
vitamin A levels and increased MTCT of HIV. In 
Malawi, investigation of 338 HIV-infected mothers 
found those with a vitamin A concentration of less 
than 0.70 μmol/L had a MTCT transmission rate of 
32.4% in comparison with 7.2% among mothers with 
a vitamin A concentration of greater than or equal 
to 1.40 μmol/L (p < 0.0001).30 
Observational data led to the implementation of 
trials investigating the efficacy of vitamin 
supplement on the prevention of MTCT. A meta-
analysis of three RCTs concluded that vitamin A 
supplementation in HIV-positive breastfeeding 
women has no significant effect on MTCT of HIV; 
combined risk ratio (RR) of 1.05, (p = 0.2). However, 
one further trial concluded a significant increase in 
MTCT rates and an increase in transmission of HIV 
during breastfeeding and vitamin A 
supplementation, with a RR 1.35 (p = 0.009).29,31 
 
Infant factors 
There are also infant factors that contribute to HIV-
1 transmission. For a breastfeeding infant, the portal 
of entry of breast milk is the mouth. However various 
mucosal surfaces are important sites through which 
HIV-1 infected beast milk can enter; these include 
the oral mucosa, tonsillar tissue, and gastrointestinal 
mucosa.8 The integrity of the gastrointestinal 
mucosal surfaces is important in the transmission of 
HIV-1 because it is the most likely site at which 
transmission occurs following the ingestion of HIV-
infected breast milk. If the mucosal surfaces of the 
intestine or mouth are damaged, e.g. in cases such 
as oral thrush, with breaks in the intestinal epithelial 
cell layer, the risk of HIV-1 transmission increases. 
Additionally, cell-associated or cell-free HIV-1 has 
the potential to cross the submucosa once the virus 
attaches itself to immature dendritic cells of the gut. 
Once attached, the cells then transport the antigen 
to the enterocytes or M cells that are specialized 




A major limitation in this literature review is that the 
studies are of diverse design. The majority of studies 
are RCT but there are also observational and cohort 
studies. This is a limitation as the type of study has 
an impact on the quality of the results; the MTCT 
rates from a RCT would be more reliable due to the 
rigorous control of the trial. Although rigorous 
control of breastfeeding regimens has proven 
benefits to infant health, it is very difficult to 
maintain in day-to-day life outside of trials, and 
therefore lacks external validity. Moreover, the trials 
may be underestimating the magnitude of the 
problem. Sample size differed between studies with 
the number of participants ranging from 425–1200 
women. This has the potential to mislead, as the 
interpretation of MTCT rate is based on the sample 
size of a particular study and, if this varies widely 
between studies, the comparison of MTCT between 
studies may not be reliable. There may be an over-
exaggeration of the results in a small study 
producing statistically significant results.  
 
A major limitation is the use of different maternal 
and infant prophylaxis ART regimens and the 
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duration of treatment. The different combinations of 
ART between the mothers and the infants meant 
that there was uncertainty in evaluating the results 
and establishing whether a correct cause-effect 
relation exists between the different types of ART 
and the impact on MTCT rates of HIV-1 in 
breastfeeding infants.  
 
Conclusion 
Breastfeeding holds great significance for infants 
and is an effective feeding option for reducing the 
risk of childhood morbidity and mortality. Since HIV-
1 can be transmitted via breast milk, prevention of 
MTCT of HIV-1 through breastfeeding remains a 
pressing public health challenge. In resource-poor 
countries, mothers face a dilemma as to which 
feeding option they should use for their infant; 
despite WHO’s recommendation, mixed feeding is 
a common practice which results in an indirect 
increase in transmission rates due to the increased 
risk of mothers obtaining mastitis. Moreover, the use 
of formula milk appears to decrease the rate of 
postnatal HIV-1 transmission, however it increases 
morbidity and mortality from other illnesses such as 
respiratory and diarrheal infections. Therefore, from 
the several studies mentioned in this review, it can 
be seen that there are many possible reasons as to 
why postnatal HIV-1 transmissions continue to 
occur, despite optimal antiretroviral treatment. If 
these risk factors are identified and further 
investigated, actions can be taken in reducing them, 
which may significantly decrease the risk of MTC 
HIV-1 transmission. 
 
What is known already: What this study adds/ highlights: 
•! Transmission of HIV is known to 
occur through breastfeeding. 
•! HAART, together with elective 
caesarean section and avoidance of 
breastfeeding, has reduced the rate 
of MTCT of HIV to below 2%. 
•! This study evaluates and highlights the significant 
differences between the HIV-1 transmission rates between 
breastfeeding and formula feeding.  
•! This study recognizes the different causative factors that 
may contribute to the increased risk of HIV-1 transmission 
through breastfeeding. 
•! This study evaluates the impact and efficacy of antiretroviral 
prophylaxis for mothers who breastfeed by comparing 
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